; Head And Neck Cancer – Pipeline Review, H1 2012
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Head And Neck Cancer – Pipeline Review, H1 2012

VIEWS: 3 PAGES: 341

Head and Neck Cancer - Pipeline Review, H1 2012', provides an overview of the Head and Neck Cancer therapeutic pipeline. This report provides information on the therapeutic development for Head and Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head and Neck Cancer. 'Head and Neck Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
  • pg 1
									       Head And Neck Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1724IDB
                                                                                           Publication Date: February 2012




Head And Neck Cancer – Pipeline Review, H1 2012                                            GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Head And Neck Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 12
    List of Figures .............................................................................................................................................................................. 16
Introduction....................................................................................................................................................................................... 17
    Global Markets Direct Report Coverage ...................................................................................................................................... 17
Head And Neck Cancer Overview .................................................................................................................................................... 18
Therapeutics Development............................................................................................................................................................... 19
    An Overview of Pipeline Products for Head And Neck Cancer .................................................................................................... 19
Head And Neck Cancer Therapeutics under Development by Companies ...................................................................................... 21
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes ....................................................................... 27
Late Stage Products ......................................................................................................................................................................... 40
    Comparative Analysis .................................................................................................................................................................. 40
Mid Clinical Stage Products.............................................................................................................................................................. 41
    Comparative Analysis .................................................................................................................................................................. 41
Early Clinical Stage Products ........................................................................................................................................................... 42
    Comparative Analysis .................................................................................................................................................................. 42
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 43
    Comparative Analysis .................................................................................................................................................................. 43
Head And Neck Cancer Therapeutics – Products under Development by Companies .................................................................... 44
Head And Neck Cancer Therapeutics – Products under Investigation by Universities/Institutes ..................................................... 51
Companies Involved in Head And Neck Cancer Therapeutics Development ................................................................................... 83
    Johnson & Johnson ..................................................................................................................................................................... 83
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 84
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 85
    Amgen Inc. .................................................................................................................................................................................. 86
    Sanofi-Aventis ............................................................................................................................................................................. 87
    AstraZeneca PLC ........................................................................................................................................................................ 88
    Eli Lilly and Company .................................................................................................................................................................. 89
    Viralytics Ltd. ............................................................................................................................................................................... 90
    GlaxoSmithKline plc .................................................................................................................................................................... 91
    YM BioSciences Inc..................................................................................................................................................................... 92
    Symphogen A/S........................................................................................................................................................................... 93
    Light Sciences Oncology, Inc. ..................................................................................................................................................... 94
    Celltrion, Inc................................................................................................................................................................................. 95
    Bio-Path Holdings, Inc. ................................................................................................................................................................ 96
    Aposense Ltd............................................................................................................................................................................... 97
    Millennium Pharmaceuticals, Inc. ................................................................................................................................................ 98
    Novartis AG ................................................................................................................................................................................. 99
    ImClone Systems Incorporated ................................................................................................................................................. 100
    Daewoong Pharmaceutical Co., Ltd. ......................................................................................................................................... 101
    Eisai Co., Ltd. ............................................................................................................................................................................ 102
    Pfizer Inc.................................................................................................................................................................................... 103



Head And Neck Cancer – Pipeline Review, H1 2012                                                                                            GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Head And Neck Cancer – Pipeline Review, H1 2012




    Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................. 104
    Takara Holdings Inc................................................................................................................................................................... 105
    Cyclacel Pharmaceuticals Inc. ................................................................................................................................................... 106
    CEL-SCI Corporation................................................................................................................................................................. 107
    Quintiles Transnational Corp. .................................................................................................................................................... 108
    SRI International ........................................................................................................................................................................ 109
    Merck KGaA .............................................................................................................................................................................. 110
    Advaxis, Inc. .............................................................................................................................................................................. 111
    Neogenix Oncology Corporation................................................................................................................................................ 112
    InNexus Biotechnology Inc. ....................................................................................................................................................... 113
    Idera Pharmaceuticals, Inc. ....................................................................................................................................................... 114
    NexMed, Inc. ............................................................................................................................................................................. 115
    Northwest Biotherapeutics, Inc. ................................................................................................................................................. 116
    Cleveland BioLabs, Inc. ............................................................................................................................................................. 117
    Oncolytics Biotech Inc. .............................................................................................................................................................. 118
    Oncothyreon Inc ........................................................................................................................................................................ 119
    Curis, Inc. .................................................................................................................................................................................. 120
    Transgene SA............................................................................................................................................................................ 121
    Jiangsu Hengrui Medicine Co., Ltd. ........................................................................................................................................... 122
    Nang Kuang Pharmaceutical Co., Ltd. ...................................................................................................................................... 123
    PCI Biotech AS .......................................................................................................................................................................... 124
    Piramal Life Sciences Limited.................................................................................................................................................... 125
    Avanti Therapeutics ................................................................................................................................................................... 126
    Wilex AG ................................................................................................................................................................................... 127
    Acceleron Pharma, Inc. ............................................................................................................................................................. 128
    Glycotope GmbH ....................................................................................................................................................................... 129
    Hawthorn Pharmaceuticals, Inc. ................................................................................................................................................ 130
    PDS Biotechnology Corporation ................................................................................................................................................ 131
    Merrimack Pharmaceuticals, Inc................................................................................................................................................ 132
    Jennerex Biotherapeutics, Inc. .................................................................................................................................................. 133
    Innogene Kalbiotech Pte Ltd...................................................................................................................................................... 134
    Vaccinogen, Inc. ........................................................................................................................................................................ 135
    Oncolys BioPharma Inc. ............................................................................................................................................................ 136
    Etubics Corporation ................................................................................................................................................................... 137
    Viventia Biotechnologies Inc. ..................................................................................................................................................... 138
    IRX Therapeutics, Inc. ............................................................................................................................................................... 139
    Pique Therapeutics.................................................................................................................................................................... 140
    Cellceutix Pharmaceuticals, Inc. ................................................................................................................................................ 141
    PNP Therapeutics, Inc............................................................................................................................................................... 142
    Eurofarma .................................................................................................................................................................................. 143
    TAU Therapeutics, LLC ............................................................................................................................................................. 144
    Boneca Corporation................................................................................................................................................................... 145
    Biotech Pharmaceuticals Co., Ltd.............................................................................................................................................. 146
    CytomX, LLC. ............................................................................................................................................................................ 147


Head And Neck Cancer – Pipeline Review, H1 2012                                                                                            GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Head And Neck Cancer – Pipeline Review, H1 2012




Head And Neck Cancer – Therapeutics Assessment..................................................................................................................... 148
    Assessment by Monotherapy Products ..................................................................................................................................... 148
    Assessment by Combination Products ...................................................................................................................................... 149
    Assessment by Route of Administration .................................................................................................................................... 150
    Assessment by Molecule Type .................................................................................................................................................. 153
Drug Profiles................................................................................................................................................................................... 156
    Sotatercept - Drug Profile .......................................................................................................................................................... 156
        Product Description............................................................................................................................................................... 156
        Mechanism of Action ............................................................................................................................................................. 156
        R&D Progress ....................................................................................................................................................................... 156
    Multikine - Drug Profile .............................................................................................................................................................. 158
        Product Description............................................................................................................................................................... 158
        Mechanism of Action ............................................................................................................................................................. 158
        R&D Progress ....................................................................................................................................................................... 158
    Tykerb - Drug Profile ................................................................................................................................................................. 160
        Product Description............................................................................................................................................................... 160
        Mechanism of Action ............................................................................................................................................................. 160
        R&D Progress ....................................................................................................................................................................... 160
    Tirazone - Drug Profile .............................................................................................................................................................. 161
        Product Description............................................................................................................................................................... 161
        Mechanism of Action ............................................................................................................................................................. 161
        R&D Progress ....................................................................................................................................................................... 161
    Cisplatin + Radiation Therapy - Drug Profile ............................................................................................................................. 162
        Product Description............................................................................................................................................................... 162
        Mechanism of Action ............................................................................................................................................................. 162
        R&D Progress ....................................................................................................................................................................... 162
    Tarceva - Drug Profile ............................................................................................................................................................... 163
        Product Description............................................................................................................................................................... 163
        Mechanism of Action ............................................................................................................................................................. 163
        R&D Progress ....................................................................................................................................................................... 163
    Proxinium - Drug Profile ............................................................................................................................................................ 165
        Product Description............................................................................................................................................................... 165
        Mechanism of Action ............................................................................................................................................................. 165
        R&D Progress ....................................................................................................................................................................... 165
    Cisplatin + Radiation Therapy - Drug Profile ............................................................................................................................. 167
        Product Description............................................................................................................................................................... 167
        Mechanism of Action ............................................................................................................................................................. 167
        R&D Progress ....................................................................................................................................................................... 167
    Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile ..................................................................................................... 169
        Product Description............................................................................................................................................................... 169
        Mechanism of Action ............................................................................................................................................................. 169
        R&D Progress ....................................................................................................................................................................... 169
    Taxotere + Cisplatin + 5-Fluorouracil + Carboplatin + Radiation Therapy - Drug Profile ........................................................... 170
        Product Description............................................................................................................................................................... 170


Head And Neck Cancer – Pipeline Review, H1 2012                                                                                           GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                 Page(4)
Head And Neck Cancer – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................. 170
        R&D Progress ....................................................................................................................................................................... 171
    Carboplatin + Radiotherapy - Drug Profile ................................................................................................................................. 172
        Product Description............................................................................................................................................................... 172
        Mechanism of Action ............................................................................................................................................................. 172
        R&D Progress ....................................................................................................................................................................... 172
    Gefitinib - Drug Profile ............................................................................................................................................................... 173
        Product Description............................................................................................................................................................... 173
        Mechanism of Action ............................................................................................................................................................. 173
        R&D Progress ....................................................................................................................................................................... 173
    Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile ................................................................................................... 175
        Product Description............................................................................................................................................................... 175
        Mechanism of Action ............................................................................................................................................................. 175
        R&D Progress ....................................................................................................................................................................... 175
    Cisplatin + Xeloda + Radiation Therapy - Drug Profile .............................................................................................................. 177
        Product Description............................................................................................................................................................... 177
        Mechanism of Action ............................................................................................................................................................. 177
        R&D Progress ....................................................................................................................................................................... 178
    Cisplatin + Cetuximab + Radiation Therapy - Drug Profile ........................................................................................................ 179
        Product Description............................................................................................................................................................... 179
        Mechanism of Action ............................................................................................................................................................. 179
        R&D Progress ....................................................................................................................................................................... 179
    Cisplatin + Radiation Therapy - Drug Profile ............................................................................................................................. 181
        Product Description............................................................................................................................................................... 181
        Mechanism of Action ............................................................................................................................................................. 181
        R&D Progress ....................................................................................................................................................................... 181
    Cisplatin + Docetaxel + Fluorouracil + Bevacizumab - Drug Profile .......................................................................................... 182
        Product Description............................................................................................................................................................... 182
        Mechanism of Action ............................................................................................................................................................. 182
        R&D Progress ....................................................................................................................................................................... 182
    Erbitux + Carboplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile ................................................................................ 184
        Product Description............................................................................................................................................................... 184
        Mechanism of Action ..........................................................................................................................................
								
To top